A newly developed small-molecule ErbB4 agonist reduces reactive cardiac fibrosis and adverse ventricular remodelling after myocardial infarction in a sex-specific manner.

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Heart failure: bench to bedside Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

ESC 365 is supported by

ESC 365 is supported by